As presented at the ESMO Gynaecological Cancers Congress 2024 (Florence, 20–22 June), a post-hoc analysis of the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial in patients with high folate receptor alpha (FRalpha), platinum-resistant ovarian cancer revealed that even those who required … Read more
by Wayne Kuznar
CHICAGO — Clinical activity and survival outcomes improved with the addition of ipilimumab (Yervoy) to nivolumab (Opdivo) in patients with ovarian or other gynecologic clear cell carcinomas, according to results from the non-comparative phase II BrUOG 354 … Read more
by Silas Inman
The addition of atezolizumab (Tecentriq) to single-agent non–platinum-based chemotherapy and bevacizumab (Avastin) did not provide any additional benefits for patients with recurrent ovarian cancer, according to the final analysis of the phase 3 AGO-OVAR 2.29/ENGOT-ov34 study (NCT03353831) … Read more
by Ariana Pelosci
Results of a recent study published in the Journal of Clinical Oncology highlighted the association of ovarian cancer with talcum powder (talc) use.1 The findings were from an extensive analysis of the Sister Study cohort.… Read more
Clearity offers emotional support to individuals with ovarian cancer through our Steps Through OC program. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our team of OC Counselors may be … Read more
by Cynthia McCormick Hibbert
For too many cancer survivors, life after treatment is fraught with a decline in cognitive function known as “chemo brain.”
A newly published study by a Northeastern professor says that yoga might hold the key to … Read more
by Sabrina Serani
The FDA announced new guidance to expand eligibility criteria with the goal of improving participation and diversity in oncology clinical trials.These 3 areas of change include laboratory values, washout periods, and performance status.
While the FDA notes … Read more
By Ryan Scott
Patients who are heavily pretreated with recurrent low-grade serous ovarian cancer (LGSOC) had high response rates, regardless of the number of prior lines of therapy received, when treated with avutometinib (previously VS-6766) plus defactinib, according to data … Read more
By Kristi Rosa
Rezatapopt (PC14586) elicited responses with a favorable toxicity profile in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations, according to data from the phase 1/2 PYNNACLE study (NCT04585750) presented at the 2024 SGO Annual … Read more
By Mark Fuerst
About half of patients with platinum-sensitive relapsed ovarian cancer (PSROC) on maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) therapy who showed RECIST progression did not have cancer antigen-125 (CA-125) progression, challenging current guidelines, according to a new study.… Read more
— “If the patients are not taking the drug, then it’s not going to work”
By Associated Press.
For cancer patients, the harsh side effects of powerful drugs have long been the trade-off for living longer. Now, patients and doctors are questioning whether all that suffering is necessary.
They’ve ignited a movement to radically change … Read more
Clearity offers emotional support to people diagnosed with ovarian cancer and their caregivers through our Steps Through OC program. If you would like personalized, one-to-one assistance with navigating the impact of an ovarian cancer diagnosis, our team of OC Counselors … Read more
By Ashley Chan
A treatment combination of avutometinib and defactinib is being evaluated in a new phase 3 trial for patients with low-grade serous ovarian cancer.
A phase 3 trial analyzing the treatment combination of avutometinib and defactinib compared with … Read more
By Edward Winstead
For people being treated for cancer, participating in virtual mind–body fitness classes may have important benefits, such as reducing the risk of being hospitalized for treatment-related problems, according to results from a clinical trial.
In the trial, … Read more
By James H. Doroshow, M.D.
More than 8 years ago, NCI launched NCI-MATCH, a first-of-its-kind precision medicine cancer clinical trial. NCI-MATCH tested different targeted therapies in people with cancer whose tumors had specific genetic changes. This year, three second-generation precision
… Read moreBy Andrea Anderson
NEW YORK – An Italian team led by investigators at Humanitas University has come up with a test for detecting early-stage high-grade serous ovarian cancer (HGSOC) that relies on DNA sequencing of cervical smear samples collected during … Read more
Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.
By Kyle Doherty
Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity. With the initiation of the phase … Read more
Clearity’s Perspective: A phase I clinical trial studying the antibody-drug conjugate (ADC) raludotatug deruxtecan (DS-6000a, R-DXd) shows early encouraging activity in heavily pretreated ovarian cancer. The antibody portion of raludotatug deruxtecan targets CDH6 (found in about 65-85% of ovarian cancers) … Read more
Clearity’s Perspective: The combination of avutometinib and defactinib has shown encouraging activity in Low-Grade Serous Ovarian Cancer. Updated results from the RAMP 201 trial suggest that the combination is active regardless of the number of prior therapies patients have received. … Read more
